Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth study shows benefits of early treatment with Enbrel

Wyeth study shows benefits of early treatment with Enbrel

16th July 2008

Wyeth Pharmaceuticals, a division of Wyeth, has announced the publication of data from the Comet trial of Enbrel (etanercept) plus methotrexate in patients with moderate-to-severe rheumatoid arthritis.

The study results, published online by the Lancet, revealed half of patients treated with Enbrel and methotrexate achieved disease activity score (DAS) clinical remission, with nearly all having no progression of joint damage.

DAS is a measure of joint swelling and tenderness as well as overall disease activity which is measured by both global health assessment and erythrocyte sedimentation rate, an objective marker of inflammation.

Enbrel is a soluble formulation of a fully human tumour necrosis factor which has 16 years collective clinical experience and an established safety profile.

Paul Emery, professor of rheumatology at the University of Leeds, said: “We hope that these data encourage physicians to use clinical remission as a new standard for evaluating symptom control in the treatment of early rheumatoid arthritis.”

He added clinical remission is highly relevant to the daily lives of patients managing their symptoms.

Last month, Amgen and Wyeth Pharmaceuticals provided the US Food and Drug Administration with information from the groups’ adverse events databases regarding Enbrel.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.